Immune responses against SIV envelope glycoprotein, using recombinant SV40 as a vaccine delivery vector

Vaccine

Volumn 20, Issue 29-30, 2002, Pages 3613-3625

  McKee, Hayley J ^a   Strayer, David S ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Lentiviruses; Lymphocyte mediated cytolysis; Vaccination

Indexed keywords

CHROMIUM 51; COMPLEMENTARY DNA; ENVELOPE PROTEIN; GLYCOPROTEIN GP 130; LENTIVIRUS VECTOR; PLASMID DNA; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ARTICLE; BIOASSAY; CELL CLONE; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; CYTOTOXIC LYMPHOCYTE; EFFECTOR CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSFECTION; IMMUNE RESPONSE; IMMUNIZATION; INOCULATION; ISOTOPE LABELING; LYMPH NODE CELL; MASTOCYTOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECOMBINANT GENE; SERUM; SIMIAN IMMUNODEFICIENCY VIRUS; SIMIAN VIRUS 40; SPLEEN CELL; TARGET CELL; VACCINIA VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT;

ANIMALS; GENE PRODUCTS, ENV; GENETIC VECTORS; IMMUNIZATION; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; SAIDS VACCINES; SIMIAN VIRUS 40; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; VACCINES, SYNTHETIC;

EID: 0037019915     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00243-8     Document Type: Article

References (62)

1. Matsushita S. Current status and future issues in the treatment of HIV-1 infection. Int. J. Hematol. 72:2000;20-27.
2. Collier A.C., Coombs R.W., Schoenfeld D.A., Bassett R.L., Timpone J., Baruch A.et al. Treatment of human immunodeficiency virus with saquinavir, zidovudine and zalcitabine: AIDS Clinical Trials Group. N. Engl. J. Med. 334:1996;1011-1017.
3. Omrani A.S., Pillay D. Multi-drug resistant HIV-1. J. Infect. 41:2000;5-11.
4. Merry C., Barry M.G., Mulcahy F., Ryan M., Heavey J., Tjia J.D.et al. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS. 11:1997;F29-F33.
5. Collier A.C., Bozzette S., Coombs R.W., Causey D.M., Schoenfeld D.A., Spector S.A.et al. A pilot study of low-dose zidovudine in human immunodeficiency virus infection. N. Engl. J. Med. 323:1990;1015-1021.
6. Finzi D., Blankson J., Siliciano J.D., Margolick J.B., Chadwick K., Pierson T.et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1a even in patients on effective combination therapy. Nat. Med. 5:1999;512-517.
7. Poznansky M.C., Coker R., Skinner C., Hill A., Bailey S., Whitaker L.et al. HIV positive patients first presenting with an AIDS defining illness: characteristics and survival. Brit. Med. J. 311:1995;156-158.
8. Connors M., Kovacs J.A., Krevat S., Gea-Banacloche J.C., Sneller M.C., Flanigan M.et al. HIV infection induces changes in CD4+ T cell phenotype and depletions within the CD4+ T cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat. Med. 3:1997;533-540.
9. Richman D.D. HIV drug resistance. AIDS Res. Hum. Retrov. 8:1992;1065-1071.
10. Burton D.R., Moore J.P. Why do we not have an HIV vaccine and how can we make one? Nat. Med. 5:1998;495-498.
11. Graziosi C., Soudeyns H., Rizzardi G.P., Bart P.-A., Chapus A., Pantaleo G. Immunopathogenesis of HIV Infection. AIDS Res. Hum. Retrov. 14:1998;S135-S142.
12. van der Groen G., Nyambi P.N., Beirnaert E., Davies D., Fransen K., Heyndrick X.et al. Genetic variation in HIV type 1: relevance of interclade variation to vaccine development. AIDS Res. Hum. Retrov. 14:1998;S211-S221.
13. Desrosiers R.C. Non-human primate models for AIDS vaccines. AIDS. 9:1995;S137-S141.
14. Johnson R.P. Macaque models for AIDS vaccine development. Curr. Opin. Immunol. 8:1996;554-560.
15. McElrath MJ, Corey L, Montefiori D, Wolff M, Schwartz D, Keeffer M, and the AIDS Vaccine Evaluation Group. A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Res. Hum. Retrov. 16;2000:907-19.
16. Letvin N.L. Progress in the development of an HIV-1 vaccine. Science. 280:1998;1875-1880.
17. Haynes B.F. HIV vaccines: where we are and where we are going. Lancet. 348:1996;933-937.
18. Cairns J.S., Sarver N. New viral vectors for HIV vaccine delivery. AIDS Res. Hum. Retrov. 14:1998;1501-1508.
19. Amara R.R., Villinger F., Altman J.D., Lydy S.L., O'Neil S.P., Staprans S.J.et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science. 292:2001;69-74.
20. Barouch D.H., Santra S., Schmitz J.E., Kuroda M.J., Fu T.-M., Wagner W.et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science. 290:2000;486-492.
21. Qui J.-T., Liu B., Tian C., Pavlakis G.N., Yu X.-F. Enhancement of primary and secondary cellular immune responses against human immunodeficiency virus type 1 gag by using DNA expression vectors that target gag antigen to the secretory pathway. J. Virol. 74:2000;5997-6005.
22. Frankel F.R., Hegde S., Lieberman J., Paterson Y. Induction of cell-mediated immune responses to human immunodeficiency virus type 1 gag protein by using Listeria monocytogenes as a live vaccine vector. J. Immunol. 155:1995;4775-4782.
23. Davis N.L., Caley I.J., Brown K.W., Betts M.R., Irlbeck D.M., McGrath K.M.et al. Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles. J. Virol. 74:2000;371-378.
24. Tartaglia J., Excler J.-L., El Habib R., Limbach K., Meignier B., Plotkin S.et al. Canarypox virus-based vaccines: prime-boost strategies to induce cell-mediated and humoral immunity against HIV. AIDS Res. Hum. Retrov. 14:1998;S291-S298.
25. Schnell M.J., Foley H.D., Siler C.A., McGettigan J.P., Dietzschold B., Pomerantz R.J. Recombinant rabies virus as potential live-viral vaccines for HIV-1. Proc. Natl. Acad. Sci. U.S.A. 97:2000;3544-3549.
26. Allen T.M., Vogel T.U., Fuller D.H., Mothe B.R., Steffen S., Boyson J.E.et al. Induction of AIDS virus-specific CTL activity in fresh unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen. J. Immunol. 164:2000;4968-4978.
27. Ramirez J.-C., Gherardi M.M., Rodriguez D., Esteban M. Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector. J. Virol. 74:2000;7651-7655.
28. Kondo R., Feitelson M.A., Strayer D.S. Use of SV40 to immunize against hepatitis B surface antigen: implications for the use of SV40 for gene transduction and its use as an immunizing agent. Gene Therapy. 5:1998;575-582.
29. Sauter B.V., Parashar B., Chowdhury N.R., Kadakol A., Ilan Y., Singh H.et al. A replication-deficient rSV40 mediates liver-directed gene transfer and a long-term amelioration of jaundice in gunn rats. Gastroenterology. 119:2000;1348-1357.
30. Strayer D.S. SV40 as an effective gene transfer vector in vivo. J. Biol. Chem. 271:1996;24741-24746.
31. McKee HJ. Aggrecan as a candidate autoantigen in rheumatoid arthritis. Ph.D. thesis. University of Newcastle, Newcastle Upon Tyne, UK, 1999. p. 51-2.
32. Swann S.A., Williams M., Story C.M., Bobbitt K.R., Fleis R., Collins K.L. HIV-1 Nef blocks transport of MHC class I molecules to the cell surface via a PI 3-kinase-dependent pathway. Virology. 282:2001;267-277.
33. Cohen G.B., Gandhi R.T., Davis D.M., Mandelboim O., Chen B.K., Strominger J.L.et al. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity. 10:1999;661-671.
34. Autran B., Hadida F., Haas G. Evolution and plasticity of CTL responses against HIV. Curr. Opin. Immunol. 8:1996;546-553.
35. McMichael A. T cell responses and viral escape. Cell. 93:1998;673-676.
36. Schmitz J.E., Kuroda M.J., Santra S., Sasseviolle V.G., Simon M.A., Lifton M.A.et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science. 283:1999;857-860.
37. Severino M.E., Sipsas N.V., Nguyen P.T., Kalams S.A., Walker B.D., Johnson R.P.et al. Inhibition of human immunodeficiency virus type 1 replication in primary CD4+ T lymphocytes, monocytes, and dendritic cells by cytotoxic T lymphocytes. J. Virol. 74:2000;6695-6699.
38. Mollet L., Li T.S., Samri A., Tournay C., Tubiana R., Calvez V.et al. The RESTIM and COMET Study Groups. Dynamics of HIV-specific CD8+ T lymphocytes with changes in viral load. J. Immunol. 165:2000;1692-1704.
39. Brand D., Lemiale F., Thibault G., Verrier B., Lebigot S., Roingeard P.et al. Antigenic properties of recombinant envelope glycoproteins derived from T cell-line-adapted isolates or primary human immunodeficiency virus isolates and their relationship to immunogenicity. Virology. 271:2000;350-362.
40. Appay V., Nixon D.F., Donahoe S.M., Gillespie G.M.A., Dong T., King A.et al. HIV-1 specific CD8+ T cells produce anti-viral cytokines but are impaired in cytolytic function. J. Exp. Med. 192:2000;63-75.
41. Ourmanov I., Brown C.R., Moss B., Carroll M., Wyatt L., Pletneva L.et al. Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) gag-pol and/or env in macaques challenged with pathogenic SIV. J. Virol. 74:2000;2740-2751.
42. Paliard X., Liu Y., Wagner R., Wolf H., Baenziger J., Walker C.M. Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques. AIDS Res. Hum. Retrov. 16:2000;273-282.
43. Tighe H., Takabayashi K., Schwartz D., Marsden R., Beck L., Corbeil J.et al. Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity. Eur. J. Immunol. 30:2000;1939-1947.
44. Lohman B.L., McChesney M.B., Miller C.J., McGowan E., Joye S.M., van Rompay K.K.et al. A partially attenuated simian immunodeficiency virus induces host immunity that correlates with resistance to pathogenic virus challenge. J. Virol. 68:1994;7021-7029.
45. Lu Y., Friedman R., Kushner N., Doling A., Thomas L., Touzjian N.et al. Genetically modified anthrax lethal toxin safely delivers whole HIV protein antigens into the cytosol to induce T cell immunity. Proc. Natl. Acad. Sci. U.S.A. 97:2000;8027-8032.
46. Rencher S.D., Lockey T.D., Srinivas R.V., Owens R.J., Hurwitz J.L. Eliciting HIV-1 envelope-specific antibodies with mixed vaccinia virus recombinants. Vaccine. 15:1997;265-272.
47. Arp J., Rovinski B., Sambhara S., Tartaglia J., Dekaban G. Human immunodeficiency virus type 1 envelope-specific cytotoxic T lymphocytes response dynamics after prime-boost vaccine regimens with human immunodeficiency virus type 1 canarypox and pseudovirions. Viral Immunol. 12:1999;281-296.
48. Molinier-Frenkel V., Gahery-Segard H., Mehtali M., Le Boulaire C., Ribault S., Boulanger P.et al. Immune response to recombinant adenovirus in humans: capsid components from viral input are targets for vector-specific cytotoxic T lymphocytes. J. Virol. 74:2000;7678-7682.
49. Excler J.L., Plotkin S. The prime-boost concept applied to HIV preventative vaccines. AIDS. 11:1997;S127-S137.
50. Chun S., Daheshia M., Lee S., Rouse B.T. Immune modulation by IL-10 gene transfer via viral vector and plasmid DNA: implication for gene therapy. Cell. Immunol. 194:1999;194-204.
51. Valmori D., Levy F., Miconnet I., Zajac P., Spagnoli G.C., Rimoldi D.et al. Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue. J. Immunol. 164:2000;1125-1131.
52. Beech J.T., Bainbridge T., Thompson S.J. Incorporation of cells into an ELISA system enhances antigen-driven lymphokine detection. J. Immunol. Meth. 205:1997;163-168.
53. Smith D.D., Cohick C.B., Lindsley H.B. Optimization of cellular ELISA for assay of surface antigens on human synoviocytes. Biotechniques. 22:1997;952-957.
54. Laybourn K.A., Hiserodt J.C., Hunt J.M., Sell S., Strayer D. Natural cell-mediated immunity in the rabbit. Cell. Immunol. 129:1990;519-527.
55. Lubaki M.N., Egan M.A., Siliciano R.F., Weinhold K.J., Bollinger R.C. A novel technique for the detection and ex-vivo expansion of HIV type 1-specific cytotoxic T lymphocytes. AIDS Res. Hum. Retrov. 10:1994;1427-1431.
56. Hel Z., Venzon D., Poudyal M., Tsai W.P., Giuliani L., Woodward R.et al. Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV 251 infection of macaques. Nat. Med. 6:2000;1140-1146.
57. Rowland-Jones S., McMichael A. Cytotoxic T lymphocytes in HIV infection. Sem. Virol. 4:1993;83-94.
58. Koup R.A., Sullivan J.L., Levine P.H., Brettler D., Mahr A., Mazzara G.et al. Detection of major histocompatibility complex class I restricted, HIV-specific cytotoxic T lymphocytes in the blood of infected hemophiliacs. Blood. 73:1989;1909-1914.
59. Atwood W.J., Norkin L.C. Class I major histocompatibility proteins as cell surface receptors for simian virus 40. J. Virol. 63:1989;4474-4477.
60. Norkin L.C. Simian virus 40 infection via class I molecules and caveolae. Immunol. Rev. 168:1999;13-22.
61. Anderson H.A., Chen Y., Norkin L.C. MHC class I molecules are enriched in caveolae but do not enter with simian virus 40. J. Gen. Virol. 79:1998;1469-1477.
62. Luborsky S.W., Chandrasekaran K. Subcellular distribution of simian virus 40 T antigen species in various cell lines: the 56K protein. Int. J. Cancer. 25:1980;517-527.